- Investing Ideas
- Swedish Pharmaceuticals & Biotech Healthy high growth potential
Swedish Pharmaceuticals & Biotech Healthy high growth potential
Results
7
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
7 companies
Camurus
Market Cap: SEK 37.6b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 631.00
7D
1.3%
1Y
-6.7%
Bonesupport Holding
Market Cap: SEK 14.9b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 226.20
7D
0%
1Y
-21.6%
BioArctic
Market Cap: SEK 29.4b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOA B
SEK 331.20
7D
1.0%
1Y
41.8%
Genovis AB (publ.)
Market Cap: SEK 1.3b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 19.60
7D
-1.4%
1Y
-17.1%
Egetis Therapeutics
Market Cap: SEK 3.2b
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
EGTX
SEK 6.94
7D
-4.0%
1Y
29.7%
Moberg Pharma
Market Cap: SEK 525.6m
A pharmaceutical company, develops and commercializes medical products primarily in Sweden.
MOB
SEK 11.14
7D
-2.3%
1Y
37.4%
AlzeCure Pharma
Market Cap: SEK 923.9m
Operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
ALZCUR
SEK 6.70
7D
-0.3%
1Y
76.3%